Trial Condition(s):

Deep vein thrombosis (DVT), pulmonary embolism (PE)

The EINSTEIN DVT study

Bayer Identifier:

11702

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2006-004495-13

Study Completed

Trial Purpose

Primary Objective:
To evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA (VKA: either warfarin or acenocoumarol) in the treatment of subjects with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolic events.

Secondary Objective:
The principal safety objective was the evaluation of major and clinically relevant non-major bleeding events.

Inclusion Criteria
-  Confirmed acute symptomatic proximal DVT without symptomatic PE
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
3449
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

For details, please refer to trial results

Additional Information